Unregistered Pharmaceuticals, their Use and Approval of Payment from Public Health Insurance

Overview

The paper presents the comparison of expenditure on unregistered pharmaceuticals in the second quarter of the year 2003 and 2004: high expenses on pharmaceuticals used for a long time and so far unregistered, newly introduced pharmaceuticals, increasing proportion of pharmaceuticals in which the registration was not renewed after their validity was finished.

Key words:
approval of unregistered pharmaceuticals by the physician reviewer – par. 16 of the law No. 48/1997 – annual increase of cost